Specialised Commissioning in the NHS – What do you need to know now

Pharma Market Access Insights - from Mtech Access

The proposed new NHSE systems for specialised commissioning are arguably the highest risk of all current dynamics, both for the NHS and for suppliers. Key aspects or policy have been published in ways that are hard to access and even harder to interpret. Here, we gather an expert panel to discuss what proposed new NHSE systems for specialised commissioning mean in practice.
In this episode, we explore:
- What’s new for Specialised Commissioning and what’s set to change?
- What are the potential implications of the proposed changes recently published?
- Integrated Care Boards (ICBs) and their increasing role with Specialised Commissioning
- What this means for the NHS and for industry in practice
The episode begins with an overview and analysis of the changes from David Thorne (Principal Associate, Mtech Access and Business Development Director, Well Up North PCN). David then opens up a broader discussion about the implications of these changes with our guest panellists James Curtis (Deputy Operational Director, Gloucestershire NHS Foundation Trust) and Mohammed Asghar (ICS Prescribing Governance Lead at Frimley Health and Care ICS).
The episode was originally broadcast as a live webinar on 2nd December 2022.
Learn more at: https://mtechaccess.co.uk/specialised-commissioning-nhs/
Find our more about our NHS Insight and Interaction services

Subscribe to our newsletter to hear more news, insights and events from Mtech Access.

Kapitel

1. Opening, Welcome and Introductions (00:00:00)

2. Specialised commissioning – the most impactful “known unknown” (00:04:47)

3. Five very basic points on specialised commissioned care (“spec comm”) (00:06:05)

4. A reminder of current and previous systems (00:09:30)

5. Three recent documents with a consistent direction of travel (00:12:47)

6. Ten consistent elements (00:14:30)

7. Panel discussion, starting with speakers' initial perspectives (00:20:58)

8. When will there be some kind of delegation and what will delegation mean? (00:27:25)

9. Who decides what medicine I have? (00:32:19)

10. How much change do you expect to see in reality? (00:36:00)

11. Where should Pharma and Medtech go for advice and information on the changes to Spec Comm? (00:41:02)

12. How aware are senior medics and clinicians in the NHS of these changes? (00:44:35)

13. Who's in charge of making sure that Specialised Commissioning is devolved and implemented according to the policy in the best way? (00:48:15)

14. Where are cancer services going? (00:51:13)

15. What areas will get addressed first? (00:52:49)

16. What would you advise Pharma / Medical Device companies to do? (00:56:44)